Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs: Appraisal consultation document

DRAFT guidance does not recommend guselkumab, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to- or who cannot tolerate previous DMARDs, as it was not considered cost-effective use of NHS resources.

Source:

National Institute for Health and Care Excellence